Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) reported third-quarter 2019 earnings of $2.79 per share, vs. $2.47 per share expected.
Revenues grew 23% to $1.26 billion, vs. $1.24 billion expected. Sales of SOLIRIS (eculizumab) came in at $990.5 million, up 12% year-over-year.
Raised FY19 revenue guidance to $4.86 – $4.89 billion vs. prior guidance of $4.75 – $4.8 billion billion.
Adjusted EPS guidance for FY19 raised to a new range of $10.25 – $10.40, vs. earlier guidance of $9.65 – $9.85.
ALXN shares rose 1.7% immediately following the announcement.
Most Popular
Context Therapeutics: Another clinical-stage oncology research firm to go public soon
The US primary markets seem to be having a record-breaking start to the year, with over $171 billion raised in the first half of 2021 compared to $168 billion for
Biogen (BIIB) Stock: Does FDA nod for Aduhelm offer a buying opportunity?
The pharmaceutical industry has been witnessing hectic activity for some time, with most drug makers either channelizing their resources for vaccine development or engaging in COVID care programs. Biotechnology giant
IPO News: Monte Rosa Therapeutics will go public this week, here are a few things to know
Biotechnology company Monte Rosa Therapeutics is slated to go public this week. In a pandemic-ridden world, this industry is expanding at a healthy pace. The global biotechnology market is estimated
